Analysts See $-0.27 EPS for Infinity Pharmaceuticals, Inc. (INFI)

March 14, 2018 - By Darrin Black

 Analysts See $ 0.27 EPS for Infinity Pharmaceuticals, Inc. (INFI)
Investors sentiment decreased to 0.47 in Q3 2017. Its down 0.16, from 0.63 in 2017Q2. It worsened, as 15 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 6 funds opened positions while 12 raised stakes. 27.30 million shares or 18.05% less from 33.31 million shares in 2017Q2 were reported.
Morgan Stanley reported 0% stake. Guggenheim Ltd invested in 15,080 shares. Platinum Investment Mngmt Limited holds 0.05% or 1.41 million shares in its portfolio. Qs Investors Limited Liability holds 0% or 182,380 shares. Art Advisors Limited Liability Co owns 181,220 shares or 0.01% of their US portfolio. Orbimed Advisors has invested 0.03% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Gp One Trading L P has invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Tortoise Inv Management Ltd Co stated it has 100 shares or 0% of all its holdings. Bogle Management L P De has 0.02% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 224,793 shares. Baker Bros L P holds 580,400 shares. American Grp holds 40,000 shares. Royal Bank & Trust Of Canada has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). 65,400 were accumulated by Numeric Investors Limited Liability. Bridgeway Cap Mngmt reported 0.01% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Goldman Sachs Gru owns 74,395 shares for 0% of their portfolio.

Since October 3, 2017, it had 1 insider buy, and 1 sale for $1.99 million activity. Perkins Adelene Q sold $13,890 worth of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Monday, March 5.

Analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report $-0.27 EPS on March, 15 after the close.They anticipate $0.19 EPS change or 41.30 % from last quarter’s $-0.46 EPS. After having $-0.14 EPS previously, Infinity Pharmaceuticals, Inc.’s analysts see 92.86 % EPS growth. The stock decreased 5.73% or $0.15 during the last trading session, reaching $2.47. About 1.09M shares traded or 35.74% up from the average. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since March 14, 2017 and is downtrending. It has underperformed by 77.66% the S&P500.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings Coverage

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. As per Friday, August 7, the company rating was maintained by RBC Capital Markets. The firm earned “Market Perform” rating on Wednesday, June 15 by Wells Fargo. downgraded the shares of INFI in report on Tuesday, June 14 to “Neutral” rating. The firm has “Neutral” rating by Wedbush given on Thursday, February 25. Morgan Stanley upgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rating on Monday, September 21. Morgan Stanley has “Overweight” rating and $13 target. As per Wednesday, June 15, the company rating was downgraded by William Blair. The rating was downgraded by JMP Securities on Tuesday, June 14 to “Market Perform”. The stock has “Underperform” rating by Wedbush on Tuesday, March 22. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, June 15. The company was downgraded on Wednesday, June 15 by Jefferies.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $125.26 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Another recent and important Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news was published by which published an article titled: “Infinity Pharmaceuticals Announces Additions to Board of Directors and …” on March 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.